HCPs: Test Your Lung Cancer Knowledge
Reviewed by: HU Medical Review Board | Last reviewed: February 2026 | Last updated: February 2026
With the lung cancer treatment landscape shifting toward earlier intervention and increasingly specific targeted therapies, staying sharp is essential. This quiz skips the basics and dives straight into the nuances of molecular resistance, staging updates, and the latest evidence from landmark trials.
Quick Quiz
Which EGFR mutation is most commonly associated with acquired resistance to first- and second-generation tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC)?
Quick Quiz
A 62-year-old female non-smoker undergoes a successful R0 resection for Stage IIB lung adenocarcinoma. Molecular testing reveals an EGFR exon 19 deletion. Following the completion of adjuvant platinum-based chemotherapy, what is the most appropriate next step to improve disease-free survival?
Quick Quiz
For patients with metastatic NSCLC harboring a MET exon 14 skipping mutation, which class of agents is specifically indicated for treatment?
Quick Quiz
In the TNM 9th edition staging system for lung cancer, how is a tumor classified if its greatest dimension is 5.5 cm and it does not involve the main bronchus or visceral pleura?
Quick Quiz
A patient with metastatic lung adenocarcinoma is found to have an EGFR exon 20 insertion mutation. The patient has recently progressed after first-line treatment with platinum-doublet chemotherapy. Which of the following drug classes is specifically indicated for this mutation type?